Phaseline

Companies › Hansa Biopharma

Hansa Biopharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Genitourinary, Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Imlifidase
IgG-degrading enzyme that cleaves IgG into F(ab')2 and Fc fragments, neutralizing Fc-media
IGHG1Phase 3Long Term Efficacy and Safety; Kidney Transplantation in Highly Sensitized PatientsFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05753930ImlifidasePhase 2Kidney Transplantation in Highly Sensitized PatientsGenitourinaryFeb 2027
NCT05937750ImlifidasePhase 3Long Term Efficacy and SafetyOtherApr 2030

Targets

IGHG1 (1)

Companies with the same targets

–

Companies built like this

Endo USA Inc., a Keenova Therapeutics Company Heron Therapeutics CUTISS Genexine Gameto

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.